DexCom is executing well with double-digit revenue growth, expanding margins, and broader adoption of G7 15 Day and Stelo. The stock remains a Hold because the business is strong, but valuation already reflects much of the upside.
DexCom(DXCM) owns a high-quality continuous glucose monitoring business with strong growth, expanding margins, and a credible path into non-insulin diabetes and metabolic health. The investment case rests on three hard facts: Q2 2026 revenue reached $1.31B, up 13% year over year; adjusted EBITDA margin reached 32.2%; and management raised full-year 2026 revenue guidance to $5.18B to $5.25B while lifting operating-margin guidance to 23.5% to 24.0%.
The business is executing well. Q2 international revenue grew 19%, the G7 15 Day rollout remained on schedule, and the CONNECT trial produced a 0.9% A1C improvement versus the control group among people with type 2 diabetes who were not using insulin. DexCom also generated more than $600M in free cash flow during the first half of 2026 and repurchased approximately $600M of stock in Q2.
The constraint is valuation. DexCom trades at 35.5x trailing earnings, 34.6x forward earnings, 6.5x enterprise value to revenue, and 1.7x PEG. Those are premium figures for a company still facing Abbott's scale, reimbursement risk, product-cycle risk, and foreign-exchange pressure. The result is a balanced medium-term stance: a strong business, but a stock that needs continued execution to justify its multiple.
That management statement is supported by the numbers. DexCom's revenue grew from $2.45B in 2021 to $4.66B in 2025, while operating income rose from $265.8M to $911.8M. The stock earns a Hold rating for moderate-risk investors because the operating story is attractive, but the current valuation leaves less room for execution mistakes.
DexCom is a San Diego-based medical device company founded in 1999 and listed on Nasdaq since 2005. It employs approximately 11,000 people and focuses on continuous glucose monitoring systems for diabetes management and metabolic health.
DexCom's core economic model combines recurring sensor purchases with software and data engagement. That structure gives successful products repeat demand rather than a one-time device sale. The practical value of the model is visible in the CONNECT trial, where median sensor wear reached 97% over 26 weeks.
The company is also broadening its addressable market. Stelo targets adults with prediabetes and type 2 diabetes who do not use insulin, while Dexcom's Smart Basal program targets insulin-management decisions. Nutrisense, acquired in Q2 2026, adds nutrition-focused insights built around CGM data.
DexCom reports its business primarily by geography rather than by separate operating segments. The United States remains the larger revenue pool, while international markets are growing faster and provide an important second engine.
U.S. revenue was $933M in Q2 2026, up 11% from $841M in Q2 2025. Management cited strong new-patient performance, share capture, and a sequential increase in U.S. new customer starts.
International revenue reached $375M, up 19% year over year, with organic growth of 16%. France and Canada were among the strongest markets after reimbursement access expanded. DexCom also launched DexCom Flex in Germany, extending its 15-day sensor strategy into selected type 2 markets.
The geographic mix gives DXCM two distinct growth levers. U.S. growth depends on converting covered patients and expanding reimbursement, while international growth benefits from market access wins and product localization. The faster international growth rate in Q2 provides useful diversification, although currency movements reduced the value of international sales.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The G7 family is DexCom's flagship platform. G7 15 Day extends sensor wear time and adds an updated algorithm, patch, customer-service improvements, and compatibility with Tandem pump users, including Mobi.
Management reported that G7 15 Day was accessible to all adult G7 customers in the United States after recent integration work. DexCom remains on track to convert nearly 50% of its U.S. customer base to the 15-day system by year-end 2026. Net promoter scores increased in each of the last three quarters.
The product matters financially as well as clinically. Management identified G7 15 Day as a contributor to gross-margin expansion, and Q2 gross margin improved approximately 400 basis points from the prior-year quarter. Longer wear time and stronger customer satisfaction support retention, while pump integrations increase the value of DexCom within automated insulin delivery systems.
Stelo is the portfolio's consumer-facing extension. Its redesigned app launched broadly in Q2 with AI-driven insights, enhanced food logging, and a more consumer-friendly interface. Stelo broadens the brand beyond intensive insulin therapy, although its revenue contribution remains smaller than the core CGM business.
DexCom's strongest advantage is the combination of clinical evidence, product experience, and interoperability. The company received the first FDA iCGM indication, supporting integration with insulin pumps and other diabetes devices. That regulatory and ecosystem position creates switching friction that a low-price sensor alone does not replicate.
The CONNECT randomized trial adds an important layer to the moat. The study enrolled nearly 300 participants across 22 U.S. primary-care sites. Over six months, the DexCom group achieved a 1.6% A1C improvement, representing a 0.9% difference versus the control group, and spent more than five additional hours per day in the normal glucose range.
The commercial evidence is also meaningful. A CVS Health real-world study reported a 66% reduction in diabetes-related hospitalization and nearly a 50% reduction in microvascular complications over three years after CGM initiation. These outcomes give DexCom a stronger reimbursement argument than a product pitch built only around convenience.
Smart Basal adds a software and clinical-workflow opportunity. In pilot practices, users reached an optimal basal dose in three weeks on average, compared with 12 weeks or longer in routine care. The program remains a pilot, so its investment value rests on execution and regulatory progress, but the measured time improvement gives the concept commercial credibility.
Operations improved materially in Q2. Gross profit reached $838.5M, or 64.1% of revenue, compared with 60.1% in the prior-year quarter. Management attributed the gain to manufacturing efficiencies, quality-management improvements, optimized shipping patterns, and the initial customer shift toward G7 15 Day.
The company is expanding its manufacturing footprint in Ireland, with commercial production scheduled for later in 2026. That investment adds operating expense before the facility fully contributes, but it also expands capacity for the international and non-insulin growth strategy.
Capital intensity remains manageable. 2025 capital expenditures were $363.5M, while the five-year cash-flow series showed $1.08B of free cash flow. Q2 2026 capital expenditures were $84.7M and quarterly free cash flow was $184.5M.
The main operating risk is scale. DexCom must coordinate sensor production, international distribution, reimbursement-driven demand, and product transitions without creating shortages or excess inventory. The Q2 margin improvement and management's reference to optimized shipping patterns show progress, but the Ireland ramp will test that discipline.
The global continuous glucose monitoring market is estimated at $15.5B in 2026 and $41.4B by 2033, representing a projected 15.1% compound annual growth rate. DexCom's 2026 revenue guidance of $5.18B to $5.25B places the company in a large and expanding category, although the market forecast does not guarantee DXCM's share of that growth.
The immediate U.S. opportunity is substantial. Management cited approximately 9 million people with CGM coverage who are not yet using the technology. Investor materials also identify more than 25 million U.S. type 2 diabetes patients who do not use insulin, with penetration around 5%.
Reimbursement is the market's central gatekeeper. DexCom reported coverage for all people with diabetes across the four largest commercial pharmacy benefit managers, representing more than 7 million type 2 diabetes patients who do not use insulin. Management expects a CMS decision before the end of 2026 and has planned for broader coverage to take effect in the middle of 2027.
The demand equation therefore has two parts: more people becoming eligible and more eligible people adopting. CONNECT strengthens the first part by supplying clinical evidence, while G7 15 Day and Stelo address ease of use and broader consumer engagement.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
DexCom serves a layered customer base. Patients and caregivers use the sensors and applications, physicians prescribe them, diabetes educators support adoption, and insurers or pharmacy benefit managers influence affordability and access.
The company's strongest customer fit is among users who value continuous data, remote monitoring, pump integration, and a reliable digital experience. The 97% median wear rate in CONNECT is a concrete sign that the product can maintain engagement among non-insulin type 2 users, a group historically viewed as harder to activate.
Physicians receive a measurable clinical argument. CONNECT produced a 0.9% A1C advantage versus control, while the CVS Health study linked CGM initiation with lower hospitalization and fewer microvascular complications. Those data points turn CGM from a monitoring accessory into a tool that can influence treatment decisions and healthcare costs.
The consumer customer is different. Stelo's redesigned app, food logging, and AI-driven insights are designed for a user who wants metabolic feedback rather than intensive diabetes management. That audience expands the funnel, but it also raises the standard for app quality, pricing, and retention.
Abbott is DexCom's most important competitor through its FreeStyle Libre franchise. Abbott has reported approximately 7 million Libre users, nearly 20% organic growth in its Diabetes Care business in 2024, and a 15% CAGR target for Libre sales. That scale gives Abbott significant manufacturing, distribution, and pricing resources.
Medtronic competes in both CGM and integrated insulin-delivery systems. Senseonics remains relevant in implantable CGM, while Roche, LifeScan, and Ascensia compete in the broader glucose-monitoring market. DexCom's annual filing also names emerging China-based companies and lower-cost or non-invasive technologies as potential threats.
DXCM's response is to compete on accuracy, usability, clinical evidence, interoperability, and customer experience rather than on price alone. The iCGM designation and pump integrations strengthen the ecosystem. G7 15 Day improves convenience, while Stelo and Nutrisense extend the data platform into nutrition and metabolic health.
The competitive weakness is concentration in a two-player market. Abbott's scale can support aggressive pricing or faster distribution, and new entrants can target specific patient groups. DexCom's 13% Q2 growth and 64.1% gross margin show that it is holding its ground, but the premium valuation assumes that product leadership continues.
Currency is the clearest macro factor in the current data. DexCom expects foreign exchange to reduce international revenue by approximately $15M in the second half of 2026 relative to its prior guidance. The company still raised its revenue midpoint because organic growth improved by more than 50 basis points at the midpoint.
Fuel and freight costs also affect the supply chain. Management cited a return to more optimized shipping patterns that helped manage the fuel-price environment in Q2. That operational response protected margins, but logistics remains a direct link between external cost pressure and profitability.
Regulation and healthcare policy carry more weight than broad economic cycles for DXCM. The FDA selected DexCom for the Tempo digital-device pilot, and Health Canada cleared G7 15 Day as its first international regulatory approval. These events support product expansion, while CMS reimbursement decisions create a separate policy risk.
The Ireland manufacturing investment also creates geographic diversification. International production can support European demand and reduce dependence on a single manufacturing footprint, although the facility's ramp adds execution risk during the transition.
DexCom generated more than $600M in free cash flow in the first half of 2026 and repurchased about $600M of stock in Q2, underscoring a balance sheet supported by strong cash generation.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q2 2026 revenue rose 13% to $1.31B while adjusted EBITDA margin reached 32.2%, with gross margin improving about 400 basis points year over year.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management lifted 2026 revenue guidance to $5.18B-$5.25B and operating-margin guidance to 23.5%-24.0%, signaling continued execution ahead.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →DexCom trades at 35.5x trailing earnings, 34.6x forward earnings, 6.5x EV/revenue, and 1.7x PEG, a rich setup for a company still facing competitive and reimbursement risks.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s valuation framework points to a $90 fair value, which supports a Hold rating rather than a more aggressive Buy.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →DexCom is one of the stronger growth-and-cash-flow stories in medical devices. The company delivered $1.31B of Q2 revenue, expanded gross margin to 64.1%, generated $184.5M of quarterly free cash flow, and raised its 2026 profitability outlook. Those are operating results with substance, not merely a polished presentation.
The longer runway is equally important. Approximately 9 million covered U.S. patients are not using CGM, more than 25 million type 2 non-insulin patients represent a broader opportunity, and the CONNECT trial gives DexCom stronger clinical support for reimbursement. G7 15 Day, Stelo, Smart Basal, Nutrisense, and the Ireland facility add several paths to future growth.
The investment decision turns on price discipline. A 35.5x trailing P/E is defensible only if growth, margins, and adoption keep moving in the same direction. At the $90.00 fair-value estimate, the stock earns a Hold for a moderate-risk, medium-term investor. A materially lower entry near $70.00 would improve the risk-reward balance, while a move above $110.00 would make the valuation increasingly difficult to defend.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
DexCom is back to a cleaner growth-and-margin profile, with double-digit revenue gains, expanding profitability, and a net cash balance supporting continued investment. The main debate is whether reimbursement expansion and international growth can offset intense CGM competition.
DexCom, Inc. (DXCM) rises after Elliott Investment Management disclosed a stake and reached a cooperation agreement with the company. The move came alongside governance changes, strong Q1 revenue growth, and raised margin guidance, giving investors a clearer case for tighter execution and continued momentum.
Mark Skousen’s The Skousen Report, published by The Oxford Club, is promoting Elon's Hit List. We trace its three targets and test the acquisition case.